KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Interest & Investment Income (2018 - 2026)

Aquestive Therapeutics has reported Interest & Investment Income over the past 8 years, most recently at $1.3 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 70.57% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $4.4 million, up 27.06%, while the annual FY2025 figure was $4.4 million, 27.06% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $1.3 million at Aquestive Therapeutics, up from $306000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $14.5 million in Q1 2023 and troughed at -$52000.0 in Q1 2021.
  • A 5-year average of $1.2 million and a median of $317500.0 in 2024 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: crashed 512.5% in 2021 and later surged 483866.67% in 2023.
  • Year by year, Interest & Investment Income stood at $135000.0 in 2021, then crashed by 51.85% to $65000.0 in 2022, then skyrocketed by 153.85% to $165000.0 in 2023, then skyrocketed by 344.85% to $734000.0 in 2024, then surged by 70.57% to $1.3 million in 2025.
  • Business Quant data shows Interest & Investment Income for AQST at $1.3 million in Q4 2025, $306000.0 in Q3 2025, and $2.1 million in Q2 2025.